/
IMDX
$5.42+$0.02 (+0.37%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$174.4M
32M shares
52-week range
$2.33 – $8.51
50% from low
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change+$2.26
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.2M | $2.2M | $958.0K | $1.5M | $1.9M | $4.1M |
| Cost of revenue | $559.0K | $344.0K | $1.9M | $778.0K | $976.0K | $1.1M | $1.1M | $3.9M |
| Gross profit | −$559.0K | −$344.0K | −$639.0K | $1.4M | −$18.0K | $413.0K | $740.0K | $190.0K |
| Gross margin | — | — | -52.5% | 64.6% | -1.9% | 27.5% | 39.3% | 4.7% |
| R&D | $6.5M | $6.8M | $9.8M | $5.0M | $7.3M | $9.3M | $9.8M | $15.9M |
| Operating income | −$15.2M | −$22.2M | −$29.7M | −$53.7M | −$18.0M | −$25.1M | −$61.0M | −$30.6M |
| EBITDA | −$15.2M | −$21.9M | −$30.5M | −$48.5M | −$13.3M | −$23.1M | −$59.0M | −$47.9M |
| Net income | −$15.8M | −$22.3M | −$29.9M | −$64.1M | −$72.9M | −$27.8M | −$60.7M | −$50.2M |
| Net margin | — | — | -2461.5% | -2916.2% | -7609.8% | -1848.4% | -3225.0% | -1238.5% |
| EPS (diluted) | -8.32 | -8.71 | -9.14 | -14.40 | -20.00 | -3.75 | -4.66 | -1.65 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.83 | $-1.39–$-0.00 | 2 |
| 2027 | $8M | $-0.85 | $-1.41–$-0.00 | 2 |
| 2028 | $29M | $-0.79 | $-1.31–$-0.00 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Insight Molecular Diagnostics Inc. Common Stock
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
www.imdxinc.com- Employees
- 58
- IPO / List date
- Dec 30, 2015
- HQ
- NASHVILLE, TN
Held by traders on TradeandTell
No one on the platform currently holds IMDX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 13,400 | $100.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IMDX yet.
